[go: up one dir, main page]

WO2013033459A3 - Compositions, methods and uses for peptides in diagnosis, progression and treatment of cancers - Google Patents

Compositions, methods and uses for peptides in diagnosis, progression and treatment of cancers Download PDF

Info

Publication number
WO2013033459A3
WO2013033459A3 PCT/US2012/053225 US2012053225W WO2013033459A3 WO 2013033459 A3 WO2013033459 A3 WO 2013033459A3 US 2012053225 W US2012053225 W US 2012053225W WO 2013033459 A3 WO2013033459 A3 WO 2013033459A3
Authority
WO
WIPO (PCT)
Prior art keywords
progression
peptides
methods
compositions
cancers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2012/053225
Other languages
French (fr)
Other versions
WO2013033459A2 (en
Inventor
Hang YIN (Hubert)
Jonel P. SALUDES
Leslie A. MORTON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Colorado Boulder
Original Assignee
University of Colorado Boulder
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Colorado Boulder filed Critical University of Colorado Boulder
Priority to US14/241,852 priority Critical patent/US20150093333A1/en
Publication of WO2013033459A2 publication Critical patent/WO2013033459A2/en
Publication of WO2013033459A3 publication Critical patent/WO2013033459A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/043—Kallidins; Bradykinins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Embodiments herein report compositions, systems, methods, and uses for diagnosing and/or treating a condition in a subject. In certain embodiments, one or more peptides can be used as biomarker detectors for predicting onset or progression of disease. Some embodiments of the present invention report peptides capable of associating with MVs for predicting onset or progression of cancer in a subject. Other embodiments include methods of generating and or modifying peptides of use herein. Yet other embodiments herein report biomarker detectors capable of detecting agents associated with cancer progression, for example, metastasis.
PCT/US2012/053225 2003-12-11 2012-08-30 Compositions, methods and uses for peptides in diagnosis, progression and treatment of cancers Ceased WO2013033459A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/241,852 US20150093333A1 (en) 2003-12-11 2012-08-30 Compositions, methods and uses for peptides in diagnosis, progression and treatment of cancers

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161528959P 2011-08-30 2011-08-30
US61/528,959 2011-08-30

Publications (2)

Publication Number Publication Date
WO2013033459A2 WO2013033459A2 (en) 2013-03-07
WO2013033459A3 true WO2013033459A3 (en) 2013-04-25

Family

ID=47757178

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/053225 Ceased WO2013033459A2 (en) 2003-12-11 2012-08-30 Compositions, methods and uses for peptides in diagnosis, progression and treatment of cancers

Country Status (1)

Country Link
WO (1) WO2013033459A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015007192A1 (en) * 2013-07-18 2015-01-22 The University Of Hong Kong Methods for classifying pleural fluid
US10189881B2 (en) * 2013-07-26 2019-01-29 The Regents Of The University Of California MPS peptides and use thereof
US10345310B2 (en) 2015-06-09 2019-07-09 The Board Of Regents Of The University Of Texas System Diagnostic test for early stage cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100099604A1 (en) * 2007-02-09 2010-04-22 Ettore Novellino Peptidic and non peptidic ligands for immunodetection of the receptor for urotensin

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100099604A1 (en) * 2007-02-09 2010-04-22 Ettore Novellino Peptidic and non peptidic ligands for immunodetection of the receptor for urotensin

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DESAI ET AL.: "The C2B Domain of Synaptotagmin Is a Ca2+?sensing Module Essential for Exocytosis", J CELL BIOLOGY, vol. 150, 5 September 2000 (2000-09-05), pages 1125 - 1135, XP055065543 *
ELZAGALLAAI ET AL.: "Platelet secretion induced by phorbol esters stimulation is mediated through phosphorylation of MARCKS: a MARCKS-derived peptide blocks MARCKS phosphorylation and serotonin release without affecting pleckstrin phosphorylation", BLOOD, vol. 95, 1 February 2000 (2000-02-01), pages 894 - 902, XP002959325 *
HERRICK ET AL.: "Position of Synaptotagmin I at the Membrane Interface: Cooperative Interactions of Tandem C2 Domains", BIOCHEMISTRY, vol. 45, 2006, pages 9668 - 9674, XP055065547 *
SALUDES ET AL.: "Detection of Highly Curved Membrane Surfaces Using a Cyclic Peptide Derived from Synaptotagmin-I", ACS CHEM BIOL, vol. 7, 6 July 2012 (2012-07-06), pages 1629 - 1635 *
SUTTON ET AL.: "Crystal Structure of the Cytosolic C2A-C2B Domains of Synaptotagmin III: Implications for Ca+2-independent SNARE Complex Interaction", J CELL BIOLOGY, vol. 147, 1999, pages 589 - 598, XP055065550 *

Also Published As

Publication number Publication date
WO2013033459A2 (en) 2013-03-07

Similar Documents

Publication Publication Date Title
NZ700823A (en) Antibodies against claudin 18.2 useful in cancer diagnosis
PH12014501164A1 (en) Anti-cd98 antibodies and methods of use thereof
WO2012054639A3 (en) Nmr systems and methods for the rapid detection of analytes
MX2013002084A (en) Biomarkers and methods of treatment.
GB2535034A (en) Methods and systems for microbiome characterization, monitoring and treatment
HK1202313A1 (en) Methods and compositions for the treatment and diagnosis of bladder cancer
WO2014160499A3 (en) Methods and compositions for detecting pancreatic cancer
MX355543B (en) Peptidomimetic macrocycles.
WO2015094995A3 (en) Gene signature biomarkers of tumor response to pd-1 antagonists
MA39776A (en) Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
WO2013106747A3 (en) Methods and compositions for the treatment and diagnosis of thyroid cancer
NZ629555A (en) Monocyte biomarkers for cancer detection
WO2014205266A3 (en) Compositions and methods for detecting and treating glioblastoma
EA201500080A1 (en) METHOD IN VITRO DIAGNOSIS AND MONITORING OF CANCER
EP3385717A3 (en) Methods of detecting prostate cancer
AR087363A1 (en) USE OF ANTIBODY I-3859 FOR THE DETECTION AND DIAGNOSIS OF CANCERES
WO2012019132A3 (en) Anaplastic lymphoma kinase in kidney cancer
MX2022007706A (en) Antibodies useful in cancer diagnosis.
EP3798316A3 (en) Genes and gene signatures for diagnosis and treatment of melanoma
NZ729773A (en) Biomarkers for disease progression in melanoma
MX2014006187A (en) Compositions and methods for prostate cancer analysis.
WO2013081645A3 (en) Erbb3 mutations in cancer
WO2013033459A3 (en) Compositions, methods and uses for peptides in diagnosis, progression and treatment of cancers
GB2510539A (en) Biomarkers of cancer
MX369175B (en) Methods and compositions for detecting and treating drug resistant akt mutant.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12828746

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 14241852

Country of ref document: US

122 Ep: pct application non-entry in european phase

Ref document number: 12828746

Country of ref document: EP

Kind code of ref document: A2